Stevenson L W, Hamilton M A, Tillisch I H, Moriguchi J D, Kobashigawa J A, Creaser J A, Drinkwater D, Laks H
Ahmanson-UCLA Cardiomyopathy Center, School of Medicine, University of Californis-Los Angeles 90024-1736.
J Am Coll Cardiol. 1991 Oct;18(4):919-25. doi: 10.1016/0735-1097(91)90747-w.
Many patients are accepted for cardiac transplantation during a period of clinical instability associated with a high risk of death, even though most can be discharged home to await transplantation. As the waiting lists lengthen, priority is awarded solely on the basis of the waiting time of outpatients, who now usually undergo transplantation after they have already survived a major period of jeopardy. To determine the impact of the current waiting times and priority system on the previously expected benefit offered by transplantation, 1-year actuarial survival without transplantation was recalculated after each month without transplantation for 214 potential candidates with an ejection fraction of 0.17 +/- 0.05 discharged on tailored medical therapy after evaluation. These data were compared with the 1-year survival data of 88 outpatients who underwent transplantation. Actuarial survival after 1 year was 67% on tailored therapy compared with 88% after transplantation (p = 0.009). Death without transplantation was sudden in 43 of 51 patients, resulting from hemodynamic decompensation in 8. For outpatients already surviving 6 months without transplantation, actuarial survival over the next 12 months was 83% without transplantation. Thus, the expected improvement in survival after transplantation would be only 5% over the subsequent year for patients waiting 6 months, which is the waiting time for many outpatients. Such patients should be reevaluated to determine whether transplantation remains indicated during the next year.
许多患者在临床不稳定且死亡风险高的时期被接受心脏移植,尽管大多数患者可以出院回家等待移植。随着等待名单的延长,优先权仅基于门诊患者的等待时间来确定,而这些患者现在通常是在经历了一段重大危险时期后才接受移植。为了确定当前的等待时间和优先系统对移植先前预期益处的影响,对214名射血分数为0.17±0.05的潜在候选人在评估后接受定制药物治疗,在每个未移植的月份后重新计算未移植情况下的1年精算生存率。将这些数据与88名接受移植的门诊患者的1年生存数据进行比较。接受定制治疗1年后的精算生存率为67%,而移植后的精算生存率为88%(p = 0.009)。51名患者中有43名未移植而突然死亡,其中8名是由于血流动力学失代偿。对于已经存活6个月未移植的门诊患者,接下来12个月未移植的精算生存率为83%。因此,对于等待6个月的患者(这是许多门诊患者的等待时间),移植后随后一年预期的生存率改善仅为5%。此类患者应重新评估,以确定在接下来的一年中是否仍需进行移植。